Patients with primary open-angle glaucoma implanted with two iStents experienced a similar IOP reduction and required fewer add-on medications compared with patients treated with a once-a-day travoprost.
While patients with glaucoma are commonly treated first with medications, the 5-year data from a prospective, randomized clinical trial suggest early surgery with two iStents (Glaukos) could provide similar IOP control when compared with once-a-day travoprost, study co-author Robert D. Fechtner, MD, of SUNY Upstate Medical University, told Ocular Surgery News.
“As we will start seeing
Uncategorized